Vertex Pharmaceuticals Incorporated (VRTX) Q3 2018 Earnings Results

Vertex Pharmaceuticals Beats on EPS, Stock Down 6.36%

Vertex Pharmaceuticals reported an EPS of $1.09, beating expectations slightly. However, the stock fell by 6.36%, indicating investor concerns despite the earnings beat. The lack of revenue information and guidance may have contributed to the negative stock reaction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.09	N/A	+5.25%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on numerical results.

Vertex Pharmaceuticals Beats on EPS, Stock Down 6.36%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceuticals Beats on EPS, Stock Down 6.36%

Key numbers

Management commentary